Acadian Asset Management
SGMT icon

Acadian Asset Management’s Sagimet Biosciences SGMT Stock Holding History

Acadian Asset Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$154K Buy
29,636
+21,656
+271% +$121K ﹤0.01% 1648
2025
Q4 		$46K Buy
+7,980
New +$57.3K ﹤0.01% 1806
2024
Q4 		– Sell
-81,777
Closed -$225K – 2105
2024
Q3 		$225K Buy
81,777
+13,326
+19% +$41.1K ﹤0.01% 1326
2024
Q2 		$232K Buy
68,451
+33,522
+96% +$154K ﹤0.01% 1395
2024
Q1 		$188K Buy
+34,929
New +$251K ﹤0.01% 1193

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management's SGMT Position: Q1 2026 in Review

Acadian Asset Management increased its Sagimet Biosciences (SGMT) stake by 271% in Q1 2026, buying an estimated $121K and bringing the position to 29,636 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

Acadian Asset Management first reported a position in SGMT in Q1 2024 and has held it in 5 quarters since. The position peaked at $232K in Q2 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Acadian Asset Management held 29,636 shares of Sagimet Biosciences worth $154K as of Q1 2026.
  • Acadian Asset Management bought 21,656 Sagimet Biosciences shares in Q1 2026, an estimated $121K.
  • Sagimet Biosciences made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1648 holding.
  • Acadian Asset Management first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 5 quarters since.
  • Acadian Asset Management's Sagimet Biosciences position peaked at $232K in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.